Prediction of disease-related miRNAs by voting with multiple classifiers

BMC Bioinformatics

Research

Changlong Gu¹  Xiaoying Li¹ 

[1] College of Information Science and Engineering, Hunan University, 410082, Changsha, Hunan, China;

关键词: miRNA similarity;    Disease similarity;    Multi-classifiers voting;    Cross-validation;    XGBoost classification;    Random forest classification;   

DOI  :  10.1186/s12859-023-05308-x

 received in 2022-12-31, accepted in 2023-04-26,  发布年份 2023

来源: Springer

【 摘 要 】

There is strong evidence to support that mutations and dysregulation of miRNAs are associated with a variety of diseases, including cancer. However, the experimental methods used to identify disease-related miRNAs are expensive and time-consuming. Effective computational approaches to identify disease-related miRNAs are in high demand and would aid in the detection of lncRNA biomarkers for disease diagnosis, treatment, and prevention. In this study, we develop an ensemble learning framework to reveal the potential associations between miRNAs and diseases (ELMDA). The ELMDA framework does not rely on the known associations when calculating miRNA and disease similarities and uses multi-classifiers voting to predict disease-related miRNAs. As a result, the average AUC of the ELMDA framework was 0.9229 for the HMDD v2.0 database in a fivefold cross-validation. All potential associations in the HMDD V2.0 database were predicted, and 90% of the top 50 results were verified with the updated HMDD V3.2 database. The ELMDA framework was implemented to investigate gastric neoplasms, prostate neoplasms and colon neoplasms, and 100%, 94%, and 90%, respectively, of the top 50 potential miRNAs were validated by the HMDD V3.2 database. Moreover, the ELMDA framework can predict isolated disease-related miRNAs. In conclusion, ELMDA appears to be a reliable method to uncover disease-associated miRNAs.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_36_Article_IEq91.gif

Fig. 4

Fig. 1

41116_2023_36_Article_IEq88.gif

41116_2023_36_Article_IEq86.gif

41116_2023_36_Article_IEq84.gif

41116_2023_36_Article_IEq83.gif

Fig. 1

41116_2023_36_Article_IEq80.gif

Fig. 3

12888_2023_4816_Article_IEq3.gif

40854_2023_494_Article_IEq2.gif

Fig. 1

41512_2023_147_Article_IEq89.gif

40517_2023_256_Article_IEq87.gif

40517_2023_256_Article_IEq85.gif

Fig. 12

Fig. 2

Fig. 9

40517_2023_256_Article_IEq73.gif

Fig. 9

Fig. 8

41512_2023_147_Article_IEq71.gif

Fig. 4

40517_2023_256_Article_IEq64.gif

Fig. 1

Fig. 3

40517_2023_256_Article_IEq60.gif

40517_2023_256_Article_IEq59.gif

Fig. 3

Fig. 2

40517_2023_256_Article_IEq53.gif

40517_2023_256_Article_IEq52.gif

40517_2023_256_Article_IEq51.gif

Fig. 2

12888_2023_4880_Article_IEq1.gif

Fig. 1

40517_2023_256_Article_IEq47.gif

Fig. 3

Fig. 2

Fig. 6

Fig. 1

Fig. 1

Fig. 7

Fig. 6

Fig. 4

40517_2023_256_Article_IEq35.gif

40517_2023_256_Article_IEq34.gif

Fig. 1

40517_2023_258_Article_IEq68.gif

40517_2023_258_Article_IEq138.gif

40517_2023_258_Article_IEq133.gif

40517_2023_258_Article_IEq132.gif

40517_2023_258_Article_IEq130.gif

40517_2023_258_Article_IEq126.gif

40517_2023_258_Article_IEq125.gif

Fig. 2

Fig. 1

40517_2023_258_Article_IEq121.gif

40517_2023_258_Article_IEq119.gif

Fig. 1

40517_2023_258_Article_IEq113.gif

Fig. 1

40517_2023_256_Article_IEq14.gif

Fig. 6

40517_2023_256_Article_IEq11.gif

40517_2023_256_Article_IEq5.gif

41116_2023_36_Article_IEq116.gif

41116_2023_36_Article_IEq818.gif

41116_2023_36_Article_IEq817.gif

41116_2023_36_Article_IEq815.gif

41116_2023_36_Article_IEq813.gif

41116_2023_36_Article_IEq811.gif

41116_2023_36_Article_IEq809.gif

41116_2023_36_Article_IEq799.gif

41116_2023_36_Article_IEq795.gif

41116_2023_36_Article_IEq789.gif

41116_2023_36_Article_IEq783.gif